| Company Name: |
HBCChem, Inc. |
| Tel: |
+1-510-219-6317 |
| Email: |
sales@hbcchem.com |
- Cyclopenthiazide
-
- $1.00
-
2026-02-02
- CAS:742-20-1
- Min. Order: 1g
- Purity: 99%
- Supply Ability: 50tons
- Cyclopenthiazide
-
- $80.00
-
2023-09-11
- CAS:742-20-1
- Min. Order: 1kg
- Purity: 99%
- Supply Ability: 10000tons
- Cyclopenthiazide
-
- $15.00
-
2021-08-12
- CAS:742-20-1
- Min. Order: 1KG
- Purity: 99%+ HPLC
|
| | Cyclopenthiazide Basic information |
| | Cyclopenthiazide Chemical Properties |
| Melting point | 230° | | Boiling point | 605.6±65.0 °C(Predicted) | | density | 1.3650 (rough estimate) | | refractive index | 1.6100 (estimate) | | storage temp. | Refrigerator | | solubility | Acetonitrile (Slightly), DMSO (Slightly), Methanol (Sparingly) | | form | Solid | | pka | 9.00±0.40(Predicted) | | color | White to Off-White | | Water Solubility | 50mg/L(room temperature) | | Major Application | pharmaceutical
pharmaceutical small molecule | | InChI | 1S/C13H18ClN3O4S2/c14-9-6-10-12(7-11(9)22(15,18)19)23(20,21)17-13(16-10)5-8-3-1-2-4-8/h6-8,13,16-17H,1-5H2,(H2,15,18,19) | | InChIKey | BKYKPTRYDKTTJY-UHFFFAOYSA-N | | SMILES | [S]1(=O)(=O)NC(Nc3c1cc(c(c3)Cl)[S](=O)(=O)N)CC2CCCC2 | | CAS DataBase Reference | 742-20-1(CAS DataBase Reference) | | EPA Substance Registry System | 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 6-chloro-3-(cyclopentylmethyl)-3,4-dihydro-, 1,1-dioxide (742-20-1) |
| WGK Germany | WGK 1 | | Storage Class | 11 - Combustible Solids | | Hazard Classifications | Acute Tox. 4 Oral | | Toxicity | LD50 in rats, mice (mg/kg): 141.8 ±24, 232.4 ±25 i.v. (Barrett) |
| | Cyclopenthiazide Usage And Synthesis |
| Uses | Cyclopenthiazide is a thiazide diuretic. Cyclopenthiazide is used in the treatment of oedema caused by conditions such as kidney disease, liver cirrhosis and pre-menstrual syndrome as well as in the treatment of hypertension. | | Uses | Antihypertensive;Sodium Chloride Symporter Inhibitor | | Definition | ChEBI: 6-chloro-3-(cyclopentylmethyl)-1,1-dioxo-3,4-dihydro-2H-1$l^{6},2,4-benzothiadiazine-7-sulfonamide is a benzothiadiazine. | | World Health Organization (WHO) | Cyclopenthiazide, a thiazide diuretic, was introduced in 1968. It
continues to be used mainly in combination drugs. | | Clinical Use | Thiazide diuretic:
Hypertension
Heart failure
Oedema | | Drug interactions | Potentially hazardous interactions with other drugs
Analgesics: increased risk of nephrotoxicity with
NSAIDs; antagonism of diuretic effect. Anti-arrhythmics: hypokalaemia leads to increased
cardiac toxicity; effects of lidocaine and mexiletine
antagonised.
Antibacterials: avoid administration with
lymecycline.
Antidepressants: increased risk of hypokalaemia
with reboxetine; enhanced hypotensive effect with
MAOIs; increased risk of postural hypotension with
tricyclics.
Antiepileptics: increased risk of hyponatraemia with
carbamazepine.
Antifungals: increased risk of hypokalaemia with
amphotericin.
Antihypertensives: enhanced hypotensive effect;
increased risk of first dose hypotension with postsynaptic alpha-blockers like prazosin; hypokalaemia
increases risk of ventricular arrhythmias with sotalol.
Antipsychotics: hypokalaemia increases risk
of ventricular arrhythmias with amisulpride;
enhanced hypotensive effect with phenothiazines;
hypokalaemia increases risk of ventricular
arrhythmias with pimozide - avoid.
Atomoxetine: hypokalaemia increases risk of
ventricular arrhythmias.
Cardiac glycosides: increased toxicity if hypokalaemia
occurs.
Ciclosporin: increased risk of nephrotoxicity and
possibly hypomagnesaemia.
Cytotoxics: increased risk of ventricular arrhythmias
due to hypokalaemia with arsenic trioxide; increased
risk of nephrotoxicity and ototoxicity with platinum
compounds.
Lithium: excretion reduced, increased toxicity | | Metabolism | Cyclopenthiazide appears to be entirely excreted
unchanged in the urine. |
| | Cyclopenthiazide Preparation Products And Raw materials |
|